Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

ConditionKeratoconus

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-55

SponsorGlaukos Corporation

About this trial

Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.

Eligibility criteria

Qualifiers

Be ≥ 18 and ≤ 55 years of age

Diagnosis of keratoconus in the study eye

Disqualifiers

Pregnant, lactating or planning a pregnancy

Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial

Trial design

Treatments tested in this trial

GLK-221 Ophthalmic Solution
Placebo Ophthalmic Solution

Treatment groups

100 Participants

are divided into 2 treatment groups

Locations

Glaukos Clinical Study Site43082, WestervilleOhio, United States

Sponsors and collaborators

Glaukos Corporation

Lead sponsor

Source ClinicalTrials.gov